Exploiting the Power of Stereochemistry in Drugs: An Overview of Racemic and Enantiopure Drugs
DOI:
https://doi.org/10.12970/2308-8044.2013.01.01.2Keywords:
Chiral drugs, chiral switch, enantiopure drugs, racemic drugs, enantiomers, biocatalysis, pharmacological profile, stereopharmacology.Abstract
Stereochemistry is one of the essential dimensions in pharmacology as it dictates how enantiomers interact with biological systems. Chirality is very important in drug design. Enantiomers of the same chiral drug can have different pharmacodynamic and/or pharmacokinetic properties. In this context, replacing some existing racemates with single isomers has resulted in improved safety and/or efficacy profile of various racemates. Single enantiomer drug use can potentially lead to simpler and more selective pharmacologic profiles, improved therapeutic indices, simpler pharmacokinetics due to different rates of metabolism of the different enantiomers, decreased drug interactions, and drug companies are increasingly using chiral switching as a marketing strategy. Additionally, due to different pharmacological activity, enantiomers of chiral drugs can differ in toxicity. However, unpredicted toxicity has been reported in some chiral switching cases which has resulted the withdrawal of the enantiomer from the market or a halt in its development. In view of above, before switching to single enantiomer drugs, prescribers should look for evidence from well-conducted clinical trials to prove that the chiral switch is cost-effective and improves the outcomes for patients rather than patents. The U.S. Food and Drug Administration (FDA) have allowed single enantiomers of generic drugs to be patented and marketed under different name. FDA regulations require that all chiral bioactive drug molecules must be isolated and tested for the efficacy and safety, and have to be as pure as possible containing a single pure enantiomer.
References
Jozwiak K, Lough WJ, Wainer IW, Eds. Drug stereochemistry: Analytical methods and pharmacology (Drugs and the pharmaceutical sciences), CRC Press, 3rd ed. 2012.
Xiaowen W, Su Z. Stereoselective metabolic and pharmacokinetic Analysis of the chiral active components from herbal medicines. Curr Pharm Anal 2010; 6(1): 39-52. http://dx.doi.org/10.2174/157341210790780221
Lin GQ, You QD, Jie-Fei Cheng JF, Eds. Chiral drugs: Chemistry and biological action, Wiley; 1st ed. 2011. http://dx.doi.org/10.1002/9781118075647
Caner H, Groner E, Levy L, Agranat I. Trends in the development of chiral drugs. Drug Discov Today 2004; 9(3): 105-10. http://dx.doi.org/10.1016/S1359-6446(03)02904-0
Stinson SC. Chiral pharmaceuticals. Chem Eng News 2001; 79(40): 79-97. http://dx.doi.org/10.1021/cen-v079n040.p079
Gulati V. Differential properties of enantiomers of commercially available racemates. J Indian Med Assoc 2007; 105(4): 173-74, 176.
Ju C, Hwang S, Cho GS, Kondaji G, Song S, Prather PL, et al. Differential anti-ischemic efficacy and therapeutic time window of trans- and cis-hinokiresinols: Stereospecific antioxidant and anti-inflammatory activities. Neuropharmacology 2013; 67: 465-75. http://dx.doi.org/10.1016/j.neuropharm.2012.12.006
Patocka J, Dvorak A. Biomedical aspects of chiral molecules. J Appl Biomed 2004; 2(2): 95-100.
Ariëns EJ. Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology Eur J Clin Pharmacol 1984; 26: 663-68. http://dx.doi.org/10.1007/BF00541922
Cahn RS, Ingold CK, Prelog V. The specification of asymmetric configuration in organic chemistry. Experienta 1956; 12: 81-124. http://dx.doi.org/10.1007/BF02157171
Nguyen LA, He H, Pham-Huy C. Chiral drugs: An overview. Int J Biomed Sci 2006; 2(2): 85-100.
Do single stereoisomer drugs provide value. Therapeutics Letter, June – Sept 2002; www.ti.ubc.ca/PDF/45.pdf
Jagan Mohan S, Chandra Mohan E, Yamsani MR. Chirality and its importance in pharmaceutical field - an overview. Interl J Pharm Sci Nanotech 2009; 1(4): 309-16.
Agranat I, Caner H, Caldwell J. Putting chirality to work: the strategy of chiral switches. Nat Rev Drug Discov 2002; 1: 753-68. http://dx.doi.org/10.1038/nrd915
Lenz W. Thalidomide and congenital anomalies. Lancet 1962; 279(7219): 45. http://dx.doi.org/10.1016/S0140-6736(62)92665-X
McConathy J, Owens MJ. Stereochemistry in drug action. J Clin Psychiat 2003; 5(2): 70-73.
Shanafelt TD, Lin T, Geyer SM, Zent CS, Leung N, Kabat B, et al. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer 2007; 109(11): 2291-98. http://dx.doi.org/10.1002/cncr.22662
Young SD, Whissell M, Noble JC, Cano PO, Lopez PG, Germond CJ. Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors. Clin Cancer Res 2006; 12(10): 3092-98. http://dx.doi.org/10.1158/1078-0432.CCR-05-2255
Sofia MJ, Bao D, Chang W, Du J, Nagarathnam D, Rachakonda S, et al. Discovery of a -d-2'-deoxy-2'- -fluoro2'--C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem 2010; 53: 7202- 18. http://dx.doi.org/10.1021/jm100863x
Lam AM, Espiritu C, Murakami E, Zennou V, Bansal S, Micolochick Steuer HM, et al. Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of -D-2'-deoxy-2'- -fluoro-2'--C-methylguanosine. Antimicrob Agents Chemother 2011; 55(6): 2566-75. http://dx.doi.org/10.1128/AAC.00032-11
Reddy PG, Bao D, Chang W, Chun BK, Du J, Nagarathnam D, et al. 2'-Deoxy-2'- -fluoro-2'--C-methyl 3',5'-cyclic phosphate nucleotide prodrug analogs as inhibitors of HCV NS5B polymerase: discovery of PSI-352938. Bioorg Med Chem Lett 2010; 20(24): 7376-80. http://dx.doi.org/10.1016/j.bmcl.2010.10.035
Singh J, Hagen TJ. Chirality and biological activity. Burger's medicinal chemistry. Drug Discovery and Development 2010; pp. 127-166.
IUPAC, 1997 IUPAC. Compendium of chemical terminology. (The “Gold book”). Compiled by McNaught AD, Wilkinson A. Blackwell scientific publications, Oxford, 2nd ed., 1997; XML on-line corrected version,Nic M, Jirat J, Kosata B, 2006; updates compiled by A. Jenkins. goldbook.iupac.org).
Kasprzyk-Hordern B, Baker D. The significance of chirality of illicit drugs for the estimation of drugs abuse using the sewage epidemiology approach. In: SETAC Europe 21st Annual Meeting, 14 May 2011-18 may 2011, Milan.
Slováková A, Hutt AJ. Chiral compounds and their pharmacologic effects. Slov Farm 1999; 48: 107-12.
Tucker GT. Chiral switches. Lancet 2000; 355: 1085-87. http://dx.doi.org/10.1016/S0140-6736(00)02047-X
Waldeck B. Three-dimensional pharmacology, a subject ranging from ignorance to overstatements. Pharmacol Toxicol 2003; 93: 203-10. http://dx.doi.org/10.1046/j.1600-0773.2003.pto930502.x
Kalyanpur M. Downstream processing in the biotechnology industry: an overview. In: Downstream processing of the proteins: Methods and protocol, Desai MA, Ed. Methods in biotechnology Vol 9, Totowa NJ, Humana Press 2000; pp. 1-10.
Milne JJ. Scale-up of protein purification: Downstream processing issues. Protein chromatography: Methods and protocols. Series: Methods Mol Biol 2010; 681: 73-85. http://dx.doi.org/10.1007/978-1-60761-913-0_5
Fraud N, Faber R, Kiss C, Demmer W, Hoerl HH, FischerFruehholz S. Hydrophobic-interaction membrane chromatography for large-scale purification of biopharmaceuticals. BioProc Int 2009; 7(S6): 30-35.
Platis D, Drossard J, Fischer R, Ma JK, Labrou NE. New downstream processing strategy for the purification of monoclonal antibodies from transgenic tobacco plants. J Chromatogr A 2008; 1211(1-2): 80-89. http://dx.doi.org/10.1016/j.chroma.2008.09.103
Pieracci J, Perry L, Conley L. Using partition designs to enhance purification process understanding. Biotechnol Bioeng 2010; 107(5): 814-24. http://dx.doi.org/10.1002/bit.22866
Arnau J, Lauritzen C, Petersen GE, Pedersen J. Current strategies for the use of affinity tags and tag removal for the purification of recombinant proteins. Protein Expr Purific 2006; 48(1): 1-13. http://dx.doi.org/10.1016/j.pep.2005.12.002
Morenweiser R. Downstream processing of viral vectors and vaccines. Gene Therapy 2005; 12(Suppl 1, Issue: S1): S103- S110.
Liu HF, Ma J, Winter C, Bayer R. Recovery and purification process development for monoclonal antibody production. MAbs 2010; 2(5): 480-99. http://dx.doi.org/10.4161/mabs.2.5.12645
Bandeira V, Peixoto C, Rodrigues AF, Cruz PE, Alves PM, Coroadinha AS, et al. Human Gene Therapy Methods 2012; 23(4): 255-63. http://dx.doi.org/10.1089/hgtb.2012.059
Riske F, Smith M, Menon M, Goetschalck S, Goidsenhoven IV, Krul A, et al. A potential generic downstream process using Cibracon Blue resin at very high loading capacity produces a highly purified monoclonal antibody preparation from cell culture harvest. J Chromatogr B: Anal Technol Biomed Life Sci 2007; 848(1): 108-15. http://dx.doi.org/10.1016/j.jchromb.2006.06.034
Chong MK, KParthasarathy K, Ng ML. Optimized sequential purification protocol for in vivo site-specific biotinylated fulllength dengue virus capsid protein. Protein Engineering, Design and Selection 2013; First published online: March 10, 2013. http://dx.doi.org/10.1093/protein/gzs107
Nicolas E, Sébastien T, Jean Marie A, Béatrice B. Impact of downstream processing on crystal quality during the precipitation of a pharmaceutical product. Powder Technol 2011; 208 (2): 337-42. http://dx.doi.org/10.1016/j.powtec.2010.08.026
Chandra Babu K, Buchi Reddy R, Naresh E, Ram Mohan K, Madhusudhan G, Mukkanti K. Enantioselective synthesis of antiepileptic drug: (-)-Levetiracetam—Synthetic applications of the versatile new chiral N- -sulfinimine. J Chem Volume 2013 (2013), Article ID 475032.
You QD. Resolution of chiral drugs. In: Chiral drugs: Chemical and biological action. Lin GQ, You QD, Cheng JF, Eds. John Wiley & Sons, Inc., 2011; pp. 137-94. http://dx.doi.org/10.1002/9781118075647.ch4
Sekhon BS. Enantioseparation of chiral drugs-An overview. Int J Pharm Tech Res 2010; 2(2): 1584-94.
Somagoni JM, Reddy S, Koorelli S, Manda S, Yamsani MR. Enantiomeric separation and determination of stereospecific drug release from marketed racemic amlodipine besylate tablets by HPLC. Pharm Anal Acta 2011; 2: 5. http://dx.doi.org/10.4172/2153-2435.1000129
Woelfle M, Seerden J-P, de Gooijer J, Pouwer K, Olliaro P, Todd MH. Resolution of praziquantel. PLoS Negl Trop Dis 2011; 5(9): e1260. http://dx.doi.org/10.1371/journal.pntd.0001260
Hashem NN. Optimization of chiral separation of nadolol by simulated moving bed technology. 2012, Electronic thesis and dissertation repository. Paper 973. http: //ir.lib.uwo.ca/etd/973.
Ward TJ, Ward KD. Chiral separation. Fundamental reviews. Anal Chem 2010; 82: 4712-22. http://dx.doi.org/10.1021/ac1010926
Ali I, Alam SD, Al-Othman ZA, Farooqi JA. Recent advances in SPE–chiral-HPLC methods for enantiomeric separation of chiral drugs in biological samples. J Chromatogr Sci 2013; First published online: January 31, 2013. http://dx.doi.org/10.1093/chromsci/bms262
Mao S. Chiral separation of racemic mandelic acid by the coupling crystallization process and simulated moving bed technology. 2012, Electronic thesis and dissertation repository. Paper 690. http: //ir.lib.uwo.ca/etd/690.
Muñoz Solano D, Hoyos P, Hernáiz MJ, Alcántara AR, Sánchez-Montero JM. Industrial biotransformations in the synthesis of building blocks leading to enantiopure drugs. Bioresource Technol 2012; 115: 196-207. http://dx.doi.org/10.1016/j.biortech.2011.11.131
van der Meijden MW, Leeman M, Gelens E, Noorduin WL, Meekes H, van Enckevort WJP, et al. Attrition-enhanced deracemization in the synthesis of Clopidogrel - A practical application of a new discovery. Org Process Res Develop 2009; 13: 1195-98. http://dx.doi.org/10.1021/op900243c
Lin GQ, You QD, Cheng JF. Chiral drugs: Chemistry and biological Action. John Wiley & Sons 08-Aug-2011.
Challener CA, Ed. Chiral Drugs. Wiley; 1 edition, December 1, 2001.
Reddy IK, Mehvar R. Chirality in Drug Design and Development. CRC Press, 01-Mar-2004; Vitomir Sunjic. Signposts to Chiral Drugs. Springer 01-Jan-2011.
Erb S. Single-enantiomer drugs poised for further market growth. Pharmaceutical technology. Pharmaceutical technology - Pharmaceutical manufacturing & development news & research for scientists. 3 Oct. 2008. Web. 21 Mar. 2011.
Agranat I, Wainschtein SR, Zusman EZ. The predicated demise of racemic new molecular entities is an exaggeration. Nature Rev Drug Discov 2012; 11: 972-73. http://dx.doi.org/10.1038/nrd3657-c1
Barratt MJ, Frail DE. Drug repositioning: Bringing new life to shelved assets and existing drugs. John Wiley & Sons 29- May-2012.
The future lies in chiral purity: A perspective. J Indian Med Assoc 2007; 105(4): 177-78.
Sun J, Liu D, Wan Z. Representative chiral drugs. In: Chiral drugs: Chemical and Biological action. Lin GQ, You QD, Cheng JF, Eds. John Wiley & Sons, Inc., 2011; pp. 401-448. http://dx.doi.org/10.1002/9781118075647.ch11
Paredes A, de Campos Lourenço T, Marzal M, Rivera A, Dorny P, Siddhartha Mahanty S, et al. In vitro analysis of albendazole sulfoxide enantiomers shows that (+)-(R)- Albendazole sulfoxide is the active enantiomer againstTaenia solium. Antimicrob Agents Chemother 2013; 57(2): 944-49. http://dx.doi.org/10.1128/AAC.01465-12
Coppola M, Mondola R. Synthetic cathinones: chemistry, pharmacology and toxicology of a new class of designer drugs of abuse marketed as bath salts or plant food. Toxicol Lett 2012; 211(2): 144-49. http://dx.doi.org/10.1016/j.toxlet.2012.03.009
Schifano F, Albanese A, Fergus S, Stair J, Deluca P, Corazza O, et al. Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues. Psychopharmacology 2011; 214(3): 593-602. http://dx.doi.org/10.1007/s00213-010-2070-x
Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, et al. 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 2011; 339(2): 530-36. http://dx.doi.org/10.1124/jpet.111.184119
Nichols AJ, Ruffolo Jr. RR, Brooks DP. The Pharmacology of fenoldopam. Am J Hypertens 1990; 3: 116S-119S.
Kinter LB, Horner E, Mann WA, Ruffolo RR, Weinstock J. Characterization of the hemodynamic activities of fenoldopam and its enantiomers in the dog. Chirality 1990; 2: 219-25. http://dx.doi.org/10.1002/chir.530020405
Avorn J. Approval of a tuberculosis drug based on a paradoxical surrogate measure. JAMA 2013; 309 (13): 1349- 50. http://dx.doi.org/10.1001/jama.2013.623
Tomassoni D, Amenta F, Amantini C, Farfariello V, Nwankwo IE, Marini C, et al. Brain activity of thioctic acid enantiomers: In vitro and in vivo studies in an animal model of cerebrovascular injury. Int J Mol Sci 2013; 14: 4580-95. http://dx.doi.org/10.3390/ijms14034580
Fletcher A, Shepherd, R. Use of (+)-mefloquine for the treatment of malaria. US 6664397 B1, 2003.
Kuthiala G, Chaudhary G. Ropivacaine: A review of its pharmacology and clinical use. Indian J Anaesth 2011; 55(2): 104-10. http://dx.doi.org/10.4103/0019-5049.79875
Tozer TN, Rowland M. Introduction to pharmacokinetics and pharmacodynamics. The quantitative basis of drug therapy. 2006. Lippincott Williams and Wilkins, Philadelphia, USA.
Hutt AJ. Chirality and pharmacokinetics: an area of neglected dimensionality? Drug Metabol Drug Interact 2007; 22(2 3): 79 112.
Dong H, Guo X, Li Z. Pharmacokinetics of chiral drugs. In Chiral drugs: Chemistry and biological action. Lin G-Q, You Q-D, Cheng J-F, Eds. John Wiley & Sons, Inc., Hoboken, NJ, USA 2011. http://dx.doi.org/10.1002/9781118075647.ch
Pharmacokinetics. In Mosby's Dictionary of Medicine, Nursing, & Health Professions. Philadelphia, PA: Elsevier Health Sciences, 2006. Retrieved from http: //www.credoreference.com/entry/6686418.
Lu H. Stereoselectivity in drug metabolism. Expert Opin Drug Metab Toxicol 2007; 3(2): 149-58. http://dx.doi.org/10.1517/17425255.3.2.149
Van Wart SA, Mager DE. Clinical pharmacokinetics and pharmacodynamics of stereoisomeric drugs. In: Józwiak K, Lough WJ, Wainer IW. Drug stereochemistry: Analytical methods and pharmacology. Edition No. 3., Informa Healthcare, April 2012 pp. 206-239.
Maddi S, Scriba G, Yamsani MR. Stereoselective binding of chiral anti-diabetic drug nateglinide to plasma proteins. Drug Metabol Drug Interact 2011; 26(2): 81-86. http://dx.doi.org/10.1515/dmdi.2011.004
Easson LH, Stedman E. Studies on the relationship between chemical constitution and physiological action. Biochem J 1933; 27: 1257-63.
Mesecar AD, Koshland DE. A new model for protein stereoselectivity. Nature 2000; 403: 614-15.
Buschmann H, Christoph T, Friderichs E, Maul C, Sundermann B, Analgesics - From chemistry & pharmacology to clinical application, Wiley-VCH 2002. http://dx.doi.org/10.1002/3527605614
Lejal N, Tarus B, Bouguyon E, Chenavas S, Bertho N, Delmas B, et al. Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus. Antimicrob Agents Chemother 2013; 57(5): 2231-42. http://dx.doi.org/10.1128/AAC.02335-12
Mentel M, Blankenfeldt W, Breinbauer R. The active site of an enzyme can host both enantiomers of a racemic ligand simultaneously. Angew Chem Int Ed 2009; 48(48): 9084-87. http://dx.doi.org/10.1002/anie.200902997
Monti JM, Mèohler H, Pandi-Peruma SR. Gaba and sleep: Molecular, functional and clinical aspects. Springer 2010. http://dx.doi.org/10.1007/978-3-0346-0226-6
Steinkopf S, Hanekam L, Schaathun M, Budnjo A, Haug BE, Nerdal W. Interaction of local anaesthetic articaine enantiomers with brain lipids: a Langmuir monolayer study. Eur J Pharm Sci 2012; 47(2): 394-401. http://dx.doi.org/10.1016/j.ejps.2012.06.010
Leffingwell JC. Chirality & bioactivity I: Pharmacology. Leffingwell Reports 2003; 3(1): 1-27.
Mather LE. Stereochemistry in anaesthetic and analgetic drugs. Minerva Anestesiol 2005; 71(9): 507-16.
Shah RR, Midgley JM, Branch SK. Stereochemical origin of some clinically significant drug safety concerns: lessons for future drug development. Adverse Drug React Toxicol Rev 1998; 17: 145-90.
Zhang XP, Loke KE, Mital S, Chahwala S, Hintze TH. Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the R+ enantiomer of amlodipine. J Cardiovasc Pharmacol 2002; 39: 208-14. http://dx.doi.org/10.1097/00005344-200202000-00007
Howland RH. Clinical implications of chirality and stereochemistry in psychopharmacology. J Psychosoc Nurs Ment Health Serv 2009; 47(8): 17-21. http://dx.doi.org/10.3928/02793695-20090722-01
Brocks DR. Drug disposition in three dimensions: an update on stereoselectivity in pharmacokinetics. Biopharm Drug Dispos 2006; 27(8): 387-406. http://dx.doi.org/10.1002/bdd.517
Nutt DJ, Feetam CL. What one hand give the other take away: some unpredicted effects of enantiomers in psychopharmacology. J Psychopharmacol 2010; 24(8): 1137-41. http://dx.doi.org/10.1177/0269881110374782
Davies NM, Teng XW. Importance of chirality in drug therapy and pharmacy practice: Implications for psychiatry. Adv Pharm 2003; 1(3): 242-52.
Ott RJ, Giacomini KM. Stereoselective transport of drugs across epithelia. In: Wainer IW, Ed. Drug stereochemistry: Analytical methods and pharmacology, 2nd edition, Marchel Dekker, New York 1993; pp. 281 314.
Maureen Rouhi A. Chirality at work: Drug developers can learn much from recent successful and failed chiral switches. Chem Engg News, May 5, 2003; pp. 56-61.
Cook CS. Current issues on bioavailability and bioequivalence determination. J Bioequiv Availab 2011; Special Issue. http://dx.doi.org/10.4172/jbb.S1-003
Torrado JJ, Blanco M, Farré M, Roset P, García-Arieta A. Rationale and conditions for the requirement of chiral bioanalytical methods in bioequivalence studies. Eur J Clin Pharmacol 2010; 66: 599-604. http://dx.doi.org/10.1007/s00228-010-0792-7
Stoschitzky K, Egginger G, Zernig G, Klein W, Lindner W. Stereoselective features of (R)- and (S)-atenolol: clinical pharmacological, pharmacokinetic, and radioligand binding studies. Chirality 1993; 5(1): 15-9. http://dx.doi.org/10.1002/chir.530050104
Pathak L, Hiremath, Kerkar PG, Manade VG. Multicentric, clinical trial of S-Amlodipine 2.5 mg versus Amlodipine 5 mg in the treatment of mild to moderate hypertension--a randomized, double-blind clinical trial. J Assoc Physicians India 2004; 52: 197-202.
Lanchote VL, Rocha A, de Albuquerque FU, Coelho EB, Bonato PS. Stereoselective analysis of fluvastatin in human plasma for pharmacokinetic studies. J Chromatogr B Biomed Sci Appl 2001; 765(1): 81-88. http://dx.doi.org/10.1016/S0378-4347(01)00407-8
Sjoerdsma A, Udenfriend S. Pharmacology and biochemistry of -methyl-dopa in man and experimental animals. Biochem Pharmacol 1961; 8: 164. http://dx.doi.org/10.1016/0006-2952(61)90738-9
Nordberg A, Wahlström G. Different interactions of steric isomers of hexobarbital to muscarinic agonist and antagonist binding sites in brain. Brain Res 1984; 310(1): 189-92. http://dx.doi.org/10.1016/0006-8993(84)90027-1
Gillespie L, Oates JA, Crout JR, Sjoerdsma M. Clinical and chemical studies with -methyldopa in patients with hypertension. Circulation 1962; 25: 281-91. http://dx.doi.org/10.1161/01.CIR.25.2.281
Esomeprazole Magnesium. The American society of healthsystem pharmacists. Retrieved 3 April 2011.
Cao H, Wang MW, Sun LX, Ikejima T, Hu ZQ, Zhao WH. Pharmacodynamic comparison of pantoprazole enantiomers: inhibition of acid-related lesions and acid secretion in rats and guinea-pigs. J Pharm Pharmacol 2005; 57: 923-27. http://dx.doi.org/10.1211/0022357056361
Charbit S, Cohen A, Ficheux H, Homerin M, Schutze F, Taccoen A. Enantiomer (-) of tenatoprazole and the therapeutic use thereof. United States Patent 7034038. 2006 April 25.
Wermuth CG. The practice of medicinal chemistry. Academic Press, 02-May-2011; p. 539.
Höglund P, Eriksson T, Björkman S. A double blind study of the sedative effects of the thalidomide enantiomers in humans. J Pharmacokinet Biopharm 1998; 26(4): 363 83. http://dx.doi.org/10.1023/A:1021008016719
Eriksson T, Björkman S, Roth B, Höglund P. Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man. J Pharm Pharmacol 2000; 52(7): 807 17. http://dx.doi.org/10.1211/0022357001774660
Heger W, Schmahl HJ, Klug S, Felies A, Nau H, Merker HJ, et al. Embryotoxic effects of thalidomide derivatives in the non human primate callithrix jacchus. IV.Teratogenicity of micrograms/kg doses of the EM12 enantiomers. Teratog Carcinog Mutagen 1994; 14(3): 115 22. http://dx.doi.org/10.1002/tcm.1770140303
Perrine DM. The chemistry of mind-altering drugs: History, pharmacology, and cultural context, American Chemical Society: Washington, DC, 1996; pp. 71-74.
Cooper MJ, Anders MW. Metabolic and pharmacodynamic interactions of enantiomers of propoxyphene and methorphan. Life Sci 1974; 15: 1665. http://dx.doi.org/10.1016/0024-3205(74)90333-6
Tobert JA. Enhancement of uricosuric properties of indacrinone by manipulation of the enantiomeric ratio. Clin Pharmacol Ther 1981; 29: 344-50.
Eeckhaut AV, Michotte V. Pharmacological importance of chiral drugs. In: Ann Van Eeckhaut, Yvette Michotte. Chiral Separations by Capillary Electrophoresis. CRC Press; 2010; pp. 1-22.
Krogsgaard-Larsen P, Liljefors T, Madsen U. Textbook of drug design and discovery. New York: Taylor and Francis 2002; p. 56.
Ibe BO, Abdallah MF, Raj JU. Mechanisms by which Salbuterol induces human bronchial smooth muscle cell proliferation. Int Arch Allergy Immunol 2008; 146(4): 321-33. http://dx.doi.org/10.1159/000121466
Millership JS, Filzpatrick A. Commonly used chiral drugs: a survey. Chirality 1993; 5(8): 573-76. http://dx.doi.org/10.1002/chir.530050802
Nunez MC, Gallo MA, Espinosa A, Campos JM. Rapis development of chiral drugs in pharmaceutical industry. In: Carlton Anthony Taft, Carlos Henrique Tomich De Paula Da Silva. New Developments in Medicinal Chemistry, Bentham Science Publishers 2010; Volume 1.
Landoni MF, Soraci A. Pharmacology of chiral compounds: 2-Arylpropionic acid derivatives. Curr Drug Metab 2001; 2(1): 37-51. http://dx.doi.org/10.2174/1389200013338810
Marzo A, Heftman E. Enantioselective analytical methods in pharmacokinetics with specific reference to genetic polymorphic metabolism. J Biochem Biophys Methods 2002; 54(1-3): 57-70. http://dx.doi.org/10.1016/S0165-022X(02)00128-8
Wang YX, Gong N, Xin YF, Hao B, Zhou XJ, Pang CCY. Biological implications of oxidation and unidirectional chiral inversion of D-amino acids. Curr Drug Metab 2012; 13: 321- 31. http://dx.doi.org/10.2174/138920012799320392
Patel BK, Hutt AJ. Stereoselectivity in drug action and disposition: An overview. In: Indra K. Reddy, Reza Mehvar. Chirality in drug design and development. CRC Press 2004; pp. 127-174.
Levy RH, Boddy AV. Stereoselectivity in pharmacokinetics: A general theory. Pharm Res 1991; 8(%): 551-56.
Brocks DR, Vakily M, Mehvar R. Stereospecific pharamacokinetics and pharmacodynamics: Selected classes of drugs. In: Indra K. Reddy, Reza Mehvar, Eds. Chirality in Drug Design and Development. CRC Press 2004. http://dx.doi.org/10.1201/9780203021811.ch7
Moore KA, Levine B. The impact of chirality in pharmacokinetics and therapeutic drug monitoring. In: Hassan Y. Aboul-Enein, Eds. Separation techniques in clinical chemistry. CRC Press, 01-Feb-2003.
Lin JH, Lu AYH. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 1997; 49(4): 403-49.
Lees P, Hunter RP, Reeves PT, Toutain PL. Pharmacokinetics and pharmacodynamics of stereoisomeric drugs with particular reference to bioequivalence determination. J Vet Pharmacol Ther 2012; 35(Suppl 1): 17- 29. http://dx.doi.org/10.1111/j.1365-2885.2012.01367.x
Kim TH. Enantioselective binding of drugs to plasma proteins. In: Józwiak K, Lough WJ, Wainer IW. Drug stereochemistry: Analytical methods and pharmacology. 3rd ed. Informa Healthcare 2012; pp. 182-205.
Wisor JP, Dement WC, Aimone L, Williams M, BozyczkoCoyne D. Armodafinil, the R-enantiomer of Modafinil: Wake-promoting effects and pharmacokinetic profile in the rat. Pharmacol Biochem Behav 2006; 85(3): 492-99. http://dx.doi.org/10.1016/j.pbb.2006.09.018
Somogyi A, Bochner F, Foster D. Inside the isomers: the tale of chiral switches. Australian Prescriber 2004; 27: 47-49.
Miura M. Enantioselective disposition of lansoprazole and rabeprazole in human plasma. Yakugaku Zasshi 2006; 126: 395-402. http://dx.doi.org/10.1248/yakushi.126.395
Williams K, Lee E. Importance of drug enantiomers in clinical pharmacology. Drugs 1985; 30: 333. http://dx.doi.org/10.2165/00003495-198530040-00003
Wainer IW. The therapeutic promise of single enantiomers: introduction. Hum Psychopharmacol Clin Exp 2001; 16: 73. http://dx.doi.org/10.1002/hup.333
Breimer DD, Van Rossum JM. Pharmacokinetics of (+)-, ( )- and (±)-hexobarbitone in man after oral administration. J Pharm Pharmacol 1973; 25: 762-64. http://dx.doi.org/10.1111/j.2042-7158.1973.tb10066.x
Hsyu PO, Drayer KM. Stereoselective renal clearance of pindolol in humans. J Clin Invest 1985; 76: 1720-26. http://dx.doi.org/10.1172/JCI112161
Svensson S, Mansfield PR. Escitalopram: superior to citalopram or a chiral chimera? Psychother Psychosom. 2004; 73(1): 10-6. http://dx.doi.org/10.1159/000074435
Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 2006; 31(2): 122-31.
Teo SK, Colburn WA, Tracewell WG, Kook KA, Stirling DI, Jaworsky MS, et al. Clinical pharmacokinetics of thalidomide. Clin Pharmacokinet 2004; 43(5): 311-27. http://dx.doi.org/10.2165/00003088-200443050-00004
Wienkers LC, Padbury GE. Stereochemical elements associated with drug metabolism and toxicity. Encyclopedia of drug metabolism and interactions 2012; 1-30.
Shimazawa R, Nagai N, Toyoshima S, Okuda H. Present state of new chiral drug development and review in Japan. J Health Sci 2008; 54(1): 23-29. http://dx.doi.org/10.1248/jhs.54.23
Smith SW. Chiral toxicology: It's the same thing…Only different. Toxicol Sci 2009; 110 (1): 4-30. http://dx.doi.org/10.1093/toxsci/kfp097
Kasprzyk-Hordern B. Pharmacologically active compounds in the environment and their chirality. Chem Soc Rev 2010; 39(11): 4466-503. http://dx.doi.org/10.1039/c000408c
Yang G, Bu HZ. Toxicology of chiral drugs. In Chiral drugs: Chemistry and biological action. Lin GQ, You QD, Cheng JF, Eds. John Wiley & Sons, Inc., Hoboken, NJ, USA 2011; Ch 10: pp. 381-400. http://dx.doi.org/10.1002/9781118075647.ch10
Castro E, Soraci A, Tapia O, Fogel F, Franci R, Denzoin L, et al. Chiral inversion of R-(-)-fenoprofen enantiomer in cats with toxic hepatic disease. J Anim Vet Adv 2006; 5(3); 176- 83.
Kashiyama E, Todaka T, Odomi M, Tanokura Y, Johnson DB, Yokoi T, et al. Stereoselective pharmacokinetics and interconversions of flosequinan enantiomers containing chiral sulphoxide in rat. Xenobiotica 1994; 24(4): 369-77. http://dx.doi.org/10.3109/00498259409045900
Kuzeff RM. A review of use of enantiomers in homeopathy. ISRN Toxicology Volume 2012 (2012), Article ID 575292.
Kuzeff RM, Topashka-Ancheva MN, Mecheva RP. Inhibition of (-)-trans-(1S,2S)-U50488 hydrochloride by its enantiomer in white mice: a placebo-controlled, randomized study. Res Complementary Classical Natural Med 2004; 11(3): 144-49. http://dx.doi.org/10.1159/000079443
Kuzeff RM, Mecheva RP, Topashka-Ancheva MN. Inhibition of (-)-propranolol hydrochloride by its enantiomer in white mice--a placebo-controlled randomized study. Forsch Komplementarmed Klass Naturheilkd 2004; 11(1): 14-19. http://dx.doi.org/10.1159/000077191
Baumann P, Eap CB. Pharmacogenetics of chiral psychotropic drugs. In: Pharmacogenetics of psychotropic drugs (Bernard Lerer, Ed.), Cambridge University Press, 2002; pp. 181-214. http://dx.doi.org/10.1017/CBO9780511543944.009
Narasimhan S, Lohoff FW. Pharmacogenetics of antidepressant drugs. Pharmacogenomics 2012; 13(4): 441- 64. http://dx.doi.org/10.2217/pgs.12.1
Nichols AI, Focht K, Jiang Q, Preskorn SH, Kane CP. Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study. Clin Drug Investig 2011; 31(3): 155-67. http://dx.doi.org/10.2165/11586630-000000000-00000
Pilgrim JL, Gerostamoulos D, Drummer OH. Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects. Forensic Sci Med Patholog 2011; 7(2): 162-84. http://dx.doi.org/10.1007/s12024-010-9188-3
Pérez-Andreu V, Roldán V, González-Conejero R, Hernández-Romero D, Vicente V, Marín F. Implications of pharmacogenetics for oral anticoagulants metabolism. Curr Drug Metab 2009; 10(6): 632-42. http://dx.doi.org/10.2174/138920009789375432
Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 2006; 58(3): 521-90. http://dx.doi.org/10.1124/pr.58.3.6
Kingbäck M, Karlsson L, Zackrisson AL, Carlsson B, Josefsson M, Bengtsson F, et al. Influence of CYP2D6 genotype on the disposition of venlafaxine and its three major metabolites in postmortem femoral blood. Forensic Sci Inter 2012; 214(1-3): 124-134.
Kingbäck M. Genetic influence on enantiomeric drug disposition: Focus on venlafaxine and citalopram. Division of Drug Research, Clinical Pharmacology, Department of Medical and Health Sciences, Linköping University, Sweden, Linköping 2011.
Branch SK, Hutt AJ. Regulatory perspective on the development of new stereoisomeric drugs. In: Józwiak K, Lough WJ, Wainer IW. Drug stereochemistry: Analytical methods and pharmacology. 3rd ed., Informa Healthcare, April 2012; pp. 240-273.
FDA’s Policy statement on the development of new stereoisomeric drugs (Sereoisomeric Drugs Policy) Fed Regist 1992; 57: FR22249.
Agranat I, Cancer H. Intellectual property and chirality of drug. Drug Discov Today 1999; 4(7): 313-21. http://dx.doi.org/10.1016/S1359-6446(99)01363-X
Srinivas NR, Barbhaiya RH, Midha KK. Enantiomeric drug development: Issues, considerations, and regulatory requirements. J Pharm Sci 2001; 90: 1205-15. http://dx.doi.org/10.1002/jps.1074
Weekes C. The importance of chiral separations in single enantiomer patent cases. In: Józwiak K, Lough WJ, Wainer IW. Drug stereochemistry: Analytical methods and pharmacology. 3rd ed., Informa Healthcare, April 2012; pp. 304-312.
Ivanova SM. Development of chiral drugs from a U.S. legal patentability perspective: Enantiomers and racemates. In: Józwiak K, Lough WJ, Wainer IW. Drug stereochemistry: Analytical methods and pharmacology. 3rd ed., Informa Healthcare, April 2012; pp. 294-303.
Patil PA, Kothekar MA. Development of safer molecules through chirality. Indian J Med Sci 2006; 60(1): 427-37. http://dx.doi.org/10.4103/0019-5359.27676
